371 related articles for article (PubMed ID: 16651442)
1. Doxorubicin-DNA adducts induce a non-topoisomerase II-mediated form of cell death.
Swift LP; Rephaeli A; Nudelman A; Phillips DR; Cutts SM
Cancer Res; 2006 May; 66(9):4863-71. PubMed ID: 16651442
[TBL] [Abstract][Full Text] [Related]
2. The cardio-protecting agent and topoisomerase II catalytic inhibitor sobuzoxane enhances doxorubicin-DNA adduct mediated cytotoxicity.
Swift LP; Cutts SM; Nudelman A; Levovich I; Rephaeli A; Phillips DR
Cancer Chemother Pharmacol; 2008 Apr; 61(5):739-49. PubMed ID: 17594094
[TBL] [Abstract][Full Text] [Related]
3. ABT-737 overcomes Bcl-2 mediated resistance to doxorubicin-DNA adducts.
Ugarenko M; Nudelman A; Rephaeli A; Kimura K; Phillips DR; Cutts SM
Biochem Pharmacol; 2010 Feb; 79(3):339-49. PubMed ID: 19737541
[TBL] [Abstract][Full Text] [Related]
4. Relationship between topoisomerase II-DNA cleavable complexes, apoptosis and cytotoxic activity of anthracyclines in human cervix carcinoma cells.
Gruber BM; Anuszewska EL; Bubko I; Gozdzik A; Priebe W; Fokt I
Anticancer Res; 2005; 25(3B):2193-8. PubMed ID: 16158963
[TBL] [Abstract][Full Text] [Related]
5. Cross-sensitivity to topoisomerase II inhibitors in cytotoxic drug-hypersensitive Chinese hamster ovary cell lines.
Robson CN; Hoban PR; Harris AL; Hickson ID
Cancer Res; 1987 Mar; 47(6):1560-5. PubMed ID: 2434220
[TBL] [Abstract][Full Text] [Related]
6. Mechanism of apoptosis induced by doxorubicin through the generation of hydrogen peroxide.
Mizutani H; Tada-Oikawa S; Hiraku Y; Kojima M; Kawanishi S
Life Sci; 2005 Feb; 76(13):1439-53. PubMed ID: 15680309
[TBL] [Abstract][Full Text] [Related]
7. Cytotoxicity and cellular uptake of doxorubicin and its formamidine derivatives in HL60 sensitive and HL60/MX2 resistant cells.
Kik K; Wasowska-Lukawska M; Oszczapowicz I; Szmigiero L
Anticancer Res; 2009 Apr; 29(4):1429-33. PubMed ID: 19414398
[TBL] [Abstract][Full Text] [Related]
8. The power and potential of doxorubicin-DNA adducts.
Cutts SM; Nudelman A; Rephaeli A; Phillips DR
IUBMB Life; 2005 Feb; 57(2):73-81. PubMed ID: 16036566
[TBL] [Abstract][Full Text] [Related]
9. Protection against Adriamycin cytotoxicity and inhibition of DNA topoisomerase II activity by 3,4-dihydroxybenzoic acid.
De Graff WG; Myers LS; Mitchell JB; Hahn SM
Int J Oncol; 2003 Jul; 23(1):159-63. PubMed ID: 12792789
[TBL] [Abstract][Full Text] [Related]
10. DNA topoisomerase II-mediated interaction of doxorubicin and daunorubicin congeners with DNA.
Bodley A; Liu LF; Israel M; Seshadri R; Koseki Y; Giuliani FC; Kirschenbaum S; Silber R; Potmesil M
Cancer Res; 1989 Nov; 49(21):5969-78. PubMed ID: 2551497
[TBL] [Abstract][Full Text] [Related]
11. Relationships between DNA damage and growth inhibition induced by topoisomerase II-interfering drugs in doxorubicin-sensitive and -resistant rat glioblastoma cells.
de Tinguy-Moreaud E; Pourquier P; Montaudon D; Robert J
Anticancer Res; 1994; 14(1A):99-103. PubMed ID: 8166463
[TBL] [Abstract][Full Text] [Related]
12. Effects of morpholinyl doxorubicins, doxorubicin, and actinomycin D on mammalian DNA topoisomerases I and II.
Wassermann K; Markovits J; Jaxel C; Capranico G; Kohn KW; Pommier Y
Mol Pharmacol; 1990 Jul; 38(1):38-45. PubMed ID: 2164630
[TBL] [Abstract][Full Text] [Related]
13. Covalent attachment of ethidium to DNA results in enhanced topoisomerase II-mediated DNA cleavage.
Marx G; Zhou H; Graves DE; Osheroff N
Biochemistry; 1997 Dec; 36(50):15884-91. PubMed ID: 9398321
[TBL] [Abstract][Full Text] [Related]
14. Induction of apoptosis by plumbagin through reactive oxygen species-mediated inhibition of topoisomerase II.
Kawiak A; Piosik J; Stasilojc G; Gwizdek-Wisniewska A; Marczak L; Stobiecki M; Bigda J; Lojkowska E
Toxicol Appl Pharmacol; 2007 Sep; 223(3):267-76. PubMed ID: 17618663
[TBL] [Abstract][Full Text] [Related]
15. 3'-Deamino-3'-morpholino-13-deoxo-10-hydroxycarminomycin conquers multidrug resistance by rapid influx following higher frequency of formation of DNA single- and double-strand breaks.
Horichi N; Tapiero H; Sugimoto Y; Bungo M; Nishiyama M; Fourcade A; Lampidis TJ; Kasahara K; Sasaki Y; Takahashi T
Cancer Res; 1990 Aug; 50(15):4698-701. PubMed ID: 2164445
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of DNA topoisomerase II by imidazoacridinones, new antineoplastic agents with strong activity against solid tumors.
Skladanowski A; Plisov SY; Konopa J; Larsen AK
Mol Pharmacol; 1996 May; 49(5):772-80. PubMed ID: 8622625
[TBL] [Abstract][Full Text] [Related]
17. Induction of topoisomerase II-mediated DNA cleavage by a protoberberine alkaloid, berberrubine.
Kim SA; Kwon Y; Kim JH; Muller MT; Chung IK
Biochemistry; 1998 Nov; 37(46):16316-24. PubMed ID: 9819224
[TBL] [Abstract][Full Text] [Related]
18. WRC-213, an l-methionine-conjugated mitoxantrone derivative, displays anticancer activity with reduced cardiotoxicity and drug resistance: identification of topoisomerase II inhibition and apoptotic machinery in prostate cancers.
Hsiao CJ; Li TK; Chan YL; Hsin LW; Liao CH; Lee CH; Lyu PC; Guh JH
Biochem Pharmacol; 2008 Feb; 75(4):847-56. PubMed ID: 18035333
[TBL] [Abstract][Full Text] [Related]
19. Topoisomerase II mediated DNA lesions induced by acridine-4-carboxamide and 2-(4-pyridyl)quinoline-8-carboxamide.
Woynarowski JM; McCarthy K; Reynolds B; Beerman TA; Denny WA
Anticancer Drug Des; 1994 Feb; 9(1):9-24. PubMed ID: 8141968
[TBL] [Abstract][Full Text] [Related]
20. DNA topoisomerase II as the primary target of anti-tumor anthracyclines.
Zunino F; Capranico G
Anticancer Drug Des; 1990 Nov; 5(4):307-17. PubMed ID: 1963303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
